Ambrisentan–tadalafil combo effective against connective tissue disease-related PAH
Combination therapy with ambrisentan plus tadalafil provides greater benefits than either agent alone in patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH), especially those with typical PAH haemodynamic characteristics at baseline, according to a posthoc analysis of the AMBITION* study.